Table 1.
Baseline demographic and clinical characteristics of the Asian subpopulation in CheckMate 9LA
| NIVO + IPI + chemoa (n = 28) | Chemob (n = 30) | |
|---|---|---|
| Age, median (range), years | 68 (46–77) | 66 (31–77) |
| < 65 years, n (%) | 10 (36) | 11 (37) |
| ≥ 65 to < 75 years, n (%) | 16 (57) | 16 (53) |
| ≥ 75 years, n (%) | 2 (7) | 3 (10) |
| Female, n (%) | 3 (11) | 6 (20) |
| Region, n (%) | ||
| Japan | 22 (79) | 28 (93) |
| China | 6 (21) | 2 (7) |
| Disease stage, n (%) | ||
| Stage IV | 24 (86) | 27 (90) |
| Recurrent | 4 (14) | 3 (10) |
| ECOG performance status, n (%) | ||
| 0 | 10 (36) | 12 (40) |
| 1 | 18 (64) | 18 (60) |
| Smoking status, n (%) | ||
| Never smoker | 2 (7) | 4 (13) |
| Current/former smoker | 26 (93) | 26 (87) |
| Histology, n (%) | ||
| Squamous | 11 (39) | 9 (30) |
| Nonsquamous | 17 (61) | 21 (70) |
| Bone metastasis, n (%) | 9 (32) | 10 (33) |
| CNS metastasis, n (%) | 6 (21) | 5 (17) |
| Liver metastasis, n (%) | 2 (7) | 5 (17) |
| Tumor PD-L1 expression,c n (%) | ||
| < 1% | 12 (43) | 13 (43) |
| ≥ 1% | 16 (57) | 17 (57) |
| 1–49% | 9 (32) | 9 (30) |
| ≥ 50% | 7 (25) | 8 (27) |
Chemo chemotherapy, CNS central nervous system, ECOG Eastern Cooperative Oncology Group, IPI ipilimumab, n number of patients, NIVO nivolumab, PD-L1 programmed death ligand-1
aNivolumab plus ipilimumab combined with chemotherapy (2 cycles)
bChemotherapy alone (4 cycles, with optional pemetrexed maintenance for nonsquamous histology)
cQuantifiable for 100% of Asian patients